high purity 99% Olaparib CAS 763113-22-0 CAS NO.763113-22-0

Hubei Langyou International Trading Co., Ltd is a renowned pharmaceutical manufacturer. We specializing in the production of research and development of pharmaceutical intermediates, this kind of products with high quality price concessions, welcomed the new and old customers advisory purchase, companies invest large fund and brain research fine chemical r&d department,biochemical,  pharmaceutical and intermediate products to meet the demand of the market. High level research team,advanced equipment and good scientific atmosphere ensure the quality .

1.Reasonable and competitive price. Provide the best and professional service.Provide the best and professional service is our purpose.

2. Reliable shipping way.Door to door service, guarantee 100% delivery for you.

We have our own shipping agent in each country,we have special lines to your country, you no need do anything.

Will finish all the customs clearance at our side, customers are without any customs issues,door to door delivery.

3.To below countries, we are very  familiar and regular.

UK,USA,Canada,Russia,Ukraine,Kazakhstan,Belarus,Germany,Poland,Sweden,the Netherlands, Australia,Spain,Mexico,Poland  and so on. All are without problems.

Product Name: Olaparib

CAS: 763113-22-0

MF: C24H23FN4O3

MW: 434.46

EINECS: 642-941-5

density 1.43

storage temp. -20°C

solubility Soluble in DMSO (up to 33 mg/ml) or in Ethanol (up to 1.7 mg/ml)

pka 12.07±0.40(Predicted)

form solid

color Off-white

Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.

Description Olaparib, marketed by AstraZeneca under the brand name Lynparza , was approved in the USA in December 2014 as a targeted, single-agent therapy for the treatment of germline BRCA-mediated advanced ovarian cancer.Olaparib, originally developed by KuDOS pharmaceuticals and later by AstraZeneca, functions as a poly ADP ribose polymerase inhibitor and has been specifically approved for patients who have received three or more treatments of chemotherapy. In clinical trials, the drug prolonged progression- free survival for patients suffering from platinum-sensitive recurrent serous ovarian cancer. Olaparib is also currently in various phases of investigation for treatment of breast, gastric, prostate, pancreatic and non-small cell lung cancer.

Chemical Properties White Solid

Uses Olaparib is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Olaparib has been shown to induce significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Recent studies show that Olaparib increases radiosensitivity of a lung tumor xenograft, making it a potential candidate for use in combination with radiotherapy.